Alkermes’ Alixorexton Shows Improved Wakefulness in Vibrance-1 Phase 2 Narcolepsy Study, Advances to Late-Stage Testing

Alkermes Inc. announced positive topline results from its Vibrance-1 Phase 2 clinical trial evaluating once-daily Alixorexton, an orexin 2 receptor agonist, in patients with Narcolepsy Type 1 (NT1). The investigational drug demonstrated significant improvements in wakefulness, the primary endpoint of the study, along with reductions in fatigue and cognitive complaints. Alixorexton was generally well tolerated by participants. These results support further development of the drug, which is now headed for late-stage testing. Alkermes is competing with companies such as Takeda and Centessa in the race to develop orexin-targeting therapies that could transform narcolepsy treatment and address other sleep disorders.